| Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding D Lapa, F Carletti, V Mazzotta, G Matusali, C Pinnetti, S Meschi, ... The Lancet Infectious Diseases 22 (9), 1267-1269, 2022 | 201 | 2022 |
| National institute for the infectious diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management E Nicastri, N Petrosillo, TA Bartoli, L Lepore, A Mondi, F Palmieri, ... Infectious disease reports 12 (1), 8543, 2020 | 159 | 2020 |
| D‟ Offizi G, Marchioni L, Murachelli S, Ippolito G, Antinori A E Nicastri, N Petrosillo, T Ascoli Bartoli, L Lepore, A Mondi, F Palmieri National Institute for the Infectious Diseases “L. Spallanzani” IRCCS …, 2020 | 151 | 2020 |
| Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study MCF Prosperi, M Fabbiani, I Fanti, M Zaccarelli, M Colafigli, A Mondi, ... BMC infectious diseases 12, 1-11, 2012 | 117 | 2012 |
| Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected … S Di Giambenedetto, M Fabbiani, E Quiros Roldan, A Latini, G D’Ettorre, ... Journal of Antimicrobial Chemotherapy 72 (4), 1163-1171, 2017 | 101 | 2017 |
| Increase in tuberculosis diagnostic delay during first wave of the COVID-19 pandemic: data from an Italian infectious disease referral hospital F Di Gennaro, G Gualano, L Timelli, P Vittozzi, V Di Bari, R Libertone, ... Antibiotics 10 (3), 272, 2021 | 89 | 2021 |
| Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons M Rotger, TR Glass, T Junier, J Lundgren, JD Neaton, ES Poloni, ... Clinical infectious diseases 57 (1), 112-121, 2013 | 84 | 2013 |
| Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human … A Antinori, S Cicalini, S Meschi, V Bordoni, P Lorenzini, A Vergori, ... Clinical Infectious Diseases 75 (1), e552-e563, 2022 | 79 | 2022 |
| Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study C Agrati, A Cossarizza, V Mazzotta, G Grassi, R Casetti, S De Biasi, ... The Lancet Infectious Diseases 23 (3), 320-330, 2023 | 74 | 2023 |
| Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort A Mondi, A Cozzi‐Lepri, A Tavelli, S Rusconi, F Vichi, ... African Journal of Reproduction and Gynaecological Endoscopy 22 (1), 2019 | 69 | 2019 |
| COVID‐19 in people living with HIV: clinical implications of dynamics of the immune response to SARS‐CoV‐2 A Mondi, E Cimini, F Colavita, S Cicalini, C Pinnetti, G Matusali, R Casetti, ... Journal of medical virology 93 (3), 1796-1804, 2021 | 62 | 2021 |
| Safety and feasibility of treatment simplification to atazanavir/ritonavir+ lamivudine in HIV-infected patients on stable treatment with two nucleos (t) ide reverse … S Di Giambenedetto, M Fabbiani, M Colafigli, N Ciccarelli, S Farina, ... Journal of Antimicrobial Chemotherapy 68 (6), 1364-1372, 2013 | 62 | 2013 |
| Efficacy and safety of treatment simplification to atazanavir/ritonavir+ lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot … A Mondi, M Fabbiani, N Ciccarelli, M Colafigli, A D'Avino, A Borghetti, ... Journal of Antimicrobial Chemotherapy 70 (6), 1843-1849, 2015 | 53 | 2015 |
| Ocular involvement in monkeypox: description of an unusual presentation during the current outbreak V Mazzotta, A Mondi, F Carletti, F Baldini, R Santoro, S Meschi, ... The Journal of Infection 85 (5), 573, 2022 | 43 | 2022 |
| Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility M Fabbiani, P Grima, B Milanini, A Mondi, E Baldonero, N Ciccarelli, ... Antiviral therapy 20 (4), 441-447, 2015 | 43 | 2015 |
| Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a … M Fabbiani, A Mondi, M Colafigli, G D’Ettorre, F Paoletti, A D’Avino, ... Scandinavian journal of infectious diseases 46 (1), 34-45, 2014 | 41 | 2014 |
| Neuropsychological screening tools in Italian HIV+ patients: A comparison of Montreal cognitive assessment (MoCA) and mini mental state examination (MMSE) B Milanini, N Ciccarelli, M Fabbiani, E Baldonero, S Limiti, R Gagliardini, ... The Clinical Neuropsychologist 30 (sup1), 1457-1468, 2016 | 29 | 2016 |
| Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy A Borghetti, G Baldin, A Ciccullo, R Gagliardini, A D'Avino, A Mondi, ... Journal of Antimicrobial Chemotherapy 71 (8), 2359-2361, 2016 | 26 | 2016 |
| Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital A Mondi, P Lorenzini, C Castilletti, R Gagliardini, E Lalle, A Corpolongo, ... International Journal of Infectious Diseases 105, 532-539, 2021 | 25 | 2021 |
| Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment G Lapadula, DP Bernasconi, S Casari, F Maggiolo, R Cauda, M Di Pietro, ... PloS one 11 (9), e0162320, 2016 | 22 | 2016 |
